SG11201601423SA - Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods - Google Patents
Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methodsInfo
- Publication number
- SG11201601423SA SG11201601423SA SG11201601423SA SG11201601423SA SG11201601423SA SG 11201601423S A SG11201601423S A SG 11201601423SA SG 11201601423S A SG11201601423S A SG 11201601423SA SG 11201601423S A SG11201601423S A SG 11201601423SA SG 11201601423S A SG11201601423S A SG 11201601423SA
- Authority
- SG
- Singapore
- Prior art keywords
- cov
- mers
- immunogenic
- compositions
- methods
- Prior art date
Links
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361880111P | 2013-09-19 | 2013-09-19 | |
| PCT/US2014/056517 WO2015042373A1 (en) | 2013-09-19 | 2014-09-19 | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201601423SA true SG11201601423SA (en) | 2016-04-28 |
Family
ID=51660661
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601423SA SG11201601423SA (en) | 2013-09-19 | 2014-09-19 | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
| SG10201802194WA SG10201802194WA (en) | 2013-09-19 | 2014-09-19 | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201802194WA SG10201802194WA (en) | 2013-09-19 | 2014-09-19 | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10751410B2 (en) |
| EP (1) | EP3046579A1 (en) |
| JP (1) | JP6643239B2 (en) |
| KR (1) | KR102399854B1 (en) |
| CN (1) | CN105555306B (en) |
| BR (1) | BR112016006122B1 (en) |
| CA (1) | CA2922258C (en) |
| HK (1) | HK1225631A1 (en) |
| IL (1) | IL244298B (en) |
| MX (1) | MX2016003419A (en) |
| RU (1) | RU2685185C2 (en) |
| SA (1) | SA516370772B1 (en) |
| SG (2) | SG11201601423SA (en) |
| WO (1) | WO2015042373A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2898067B1 (en) * | 2012-09-23 | 2020-01-15 | Erasmus University Medical Center Rotterdam | Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor |
| US9889194B2 (en) | 2013-03-01 | 2018-02-13 | New York Blood Center, Inc. | Immunogenic composition for MERS coronavirus infection |
| AU2014354797C1 (en) | 2013-11-29 | 2018-02-01 | Inovio Pharmaceuticals, Inc. | MERS-CoV vaccine |
| US11103575B2 (en) | 2014-02-28 | 2021-08-31 | The New York Blood Center, Inc. | Immunogenic composition for MERS coronavirus infection |
| WO2018094241A1 (en) * | 2016-11-18 | 2018-05-24 | New York Blood Center, Inc. | Immunogenic composition for mers coronavirus infection |
| JP2017006008A (en) * | 2015-06-17 | 2017-01-12 | オーストリッチファーマ株式会社 | Antibody and antiserum against mers |
| AU2016315478B2 (en) | 2015-09-03 | 2023-07-13 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| CN106119213A (en) * | 2016-06-20 | 2016-11-16 | 中国疾病预防控制中心病毒病预防控制所 | MERS CoV mosaic type VLPs vaccine with influenza virus M1 as skeleton |
| KR20180058206A (en) * | 2016-11-23 | 2018-05-31 | 에스케이케미칼 주식회사 | Immunogenic Middle East Respiratory Syndrome Coronavirus (MERS-CoV) S protein composition and producing method thereof |
| KR102167727B1 (en) * | 2017-06-21 | 2020-10-20 | 경희대학교 산학협력단 | A method for producing MERS antigen using Drosophila melanogastor S2 |
| KR101895228B1 (en) * | 2017-08-23 | 2018-10-30 | 대한민국 | Monoclonal antibody against spike protein of middle east respiratory syndrome coronavirus and uses therof |
| AU2019238171A1 (en) | 2018-03-19 | 2020-09-24 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
| AU2021214064A1 (en) * | 2020-01-27 | 2022-08-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| US11202753B1 (en) | 2020-03-06 | 2021-12-21 | Aquavit Pharmaceuticals, Inc. | Systems and methods for generating immune responses in subjects using microchannel delivery devices |
| CN111484560A (en) * | 2020-03-24 | 2020-08-04 | 深圳市华启生物科技有限公司 | Coronavirus model and application thereof |
| CN111450047A (en) * | 2020-03-25 | 2020-07-28 | 天津大学 | Method for synthesizing MERS virus immune gel preparation |
| WO2021215857A1 (en) * | 2020-04-22 | 2021-10-28 | 포항공과대학교 산학협력단 | Coronavirus disease 2019 (covid-19) recombinant spike protein forming trimer, method for mass producing recombinant spike protein in plants, and method for preparing vaccine composition on basis thereof |
| US11129890B1 (en) * | 2020-05-19 | 2021-09-28 | Vigene Biosciences, Inc. | Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein |
| CN115838433A (en) * | 2020-10-27 | 2023-03-24 | 中国科学院微生物研究所 | Beta coronavirus polymer antigen, preparation method and application thereof |
| WO2022115503A1 (en) * | 2020-11-25 | 2022-06-02 | Dupont Nutrition Biosciences Aps | Treatment and prevention of coronavirus infection |
| CN114057894B (en) * | 2021-06-18 | 2022-08-05 | 国药中生生物技术研究院有限公司 | Novel recombinant coronavirus RBD trimer protein vaccine capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1544007A (en) | 1921-08-11 | 1925-06-30 | Hughes Arthur Sheridan | Toilet partition |
| US4520019A (en) | 1982-04-29 | 1985-05-28 | Ribi Immunochem Research, Inc. | Stable composition and preparation thereof |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4505899A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4505900A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4435386A (en) | 1982-05-26 | 1984-03-06 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4436728A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
| US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
| WO2003068933A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
| SE0300795D0 (en) | 2003-03-24 | 2003-03-24 | Isconova Ab | Composition comprising iscom particles and live micro-organisms |
| WO2004085633A1 (en) * | 2003-03-24 | 2004-10-07 | The University Of Hong Kong | A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof |
| CN1237184C (en) * | 2003-06-03 | 2006-01-18 | 中国科学院上海药物研究所 | Target for medicine against SARS-Cov and medicine screening method and medicine against SARS |
| JP5763344B2 (en) * | 2007-12-17 | 2015-08-12 | メディカル リサーチ カウンシル テクノロジー | Hepatitis C virus antibody |
| BRPI0922867B8 (en) | 2008-12-09 | 2021-05-25 | Novavax Inc | respiratory syncytial virus (rsv) fusion glycoprotein (f), isolated nucleic acid, host cell, vaccine composition and purified micelle |
| WO2011005183A1 (en) | 2009-07-10 | 2011-01-13 | Isconova Ab | New composition |
| RU2403063C1 (en) * | 2009-08-28 | 2010-11-10 | Автономная некоммерческая организация "Научно-исследовательский институт диагностики и профилактики болезней человека и животных" (АНО "НИИ ДПБ") | Inactivated combined vaccine against viral diarrhea, rota-, corona-virus diseases and escherichiosis of cattle |
-
2014
- 2014-09-19 MX MX2016003419A patent/MX2016003419A/en unknown
- 2014-09-19 CA CA2922258A patent/CA2922258C/en active Active
- 2014-09-19 SG SG11201601423SA patent/SG11201601423SA/en unknown
- 2014-09-19 EP EP14780994.1A patent/EP3046579A1/en active Pending
- 2014-09-19 US US15/023,629 patent/US10751410B2/en active Active
- 2014-09-19 WO PCT/US2014/056517 patent/WO2015042373A1/en active Application Filing
- 2014-09-19 RU RU2016111934A patent/RU2685185C2/en active
- 2014-09-19 JP JP2016544012A patent/JP6643239B2/en active Active
- 2014-09-19 KR KR1020167007733A patent/KR102399854B1/en active IP Right Grant
- 2014-09-19 SG SG10201802194WA patent/SG10201802194WA/en unknown
- 2014-09-19 BR BR112016006122-5A patent/BR112016006122B1/en active IP Right Grant
- 2014-09-19 CN CN201480051512.9A patent/CN105555306B/en active Active
-
2016
- 2016-02-25 IL IL244298A patent/IL244298B/en active IP Right Grant
- 2016-03-17 SA SA516370772A patent/SA516370772B1/en unknown
- 2016-12-08 HK HK16113985A patent/HK1225631A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2922258C (en) | 2022-11-29 |
| JP2016536346A (en) | 2016-11-24 |
| RU2016111934A3 (en) | 2018-03-22 |
| US10751410B2 (en) | 2020-08-25 |
| RU2685185C2 (en) | 2019-04-16 |
| EP3046579A1 (en) | 2016-07-27 |
| BR112016006122A2 (en) | 2017-09-26 |
| IL244298B (en) | 2021-06-30 |
| KR102399854B1 (en) | 2022-05-19 |
| CN105555306A (en) | 2016-05-04 |
| US20160206729A1 (en) | 2016-07-21 |
| BR112016006122B1 (en) | 2023-11-14 |
| RU2016111934A (en) | 2017-10-05 |
| CA2922258A1 (en) | 2015-03-26 |
| CN105555306B (en) | 2019-12-03 |
| WO2015042373A1 (en) | 2015-03-26 |
| HK1225631A1 (en) | 2017-09-15 |
| MX2016003419A (en) | 2016-10-10 |
| IL244298A0 (en) | 2016-04-21 |
| SA516370772B1 (en) | 2023-01-08 |
| JP6643239B2 (en) | 2020-02-12 |
| SG10201802194WA (en) | 2018-05-30 |
| KR20160055164A (en) | 2016-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1225631A1 (en) | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods | |
| IL273205A (en) | Compositions and methods | |
| HK1218837A1 (en) | Compositions and methods | |
| HK1218560A1 (en) | Compositions and methods | |
| HK1214962A1 (en) | Influenza virus immunogenic compositions and uses thereof | |
| GB2520795B (en) | Compositions and methods | |
| IL246280B (en) | Therapeutic methods and compositions | |
| IL239840A0 (en) | Polymyxins, compositions, methods of making and methods of use | |
| EP2981529A4 (en) | Oridonin analogs, compositions, and methods related thereto | |
| IL242795B (en) | Compositions, methods, and devices for dialysis | |
| GB201305813D0 (en) | Compositions and methods | |
| HK1213800A1 (en) | Toxoid, compositions and related methods | |
| IL240194B (en) | Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer | |
| IL243778A0 (en) | Combination immunogenic compositions | |
| EP3008176A4 (en) | Compositions and methods for enhancing virus replication | |
| HK1220358A1 (en) | Compositions and methods for live, attenuated alphavirus formulations | |
| SG11201510617WA (en) | Methods and compositions for dengue virus vaccines | |
| EP3041503A4 (en) | Methods and compositions for viral vectored vaccines | |
| HK1213917A1 (en) | Toxoid, compositions and related methods | |
| HK1217670A1 (en) | Formulations of albu-bche, preparation and uses thereof albu-bche | |
| GB201313990D0 (en) | Combination immunogenic compositions | |
| GB201322617D0 (en) | Methods and compositions | |
| GB201322508D0 (en) | Dental frameworks and related methods | |
| GB201319255D0 (en) | Therapeutic compositions and methods | |
| GB201312393D0 (en) | Compositions and Methods |